CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-13 | Kalin Katherine Bach Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2022-03-14 | Francomano Robert Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2022-01-31 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Grant or award | +13,000 | 55,028 | ||
| 2022-01-31 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Grant or award · Stock Option (Right to Buy) | +48,750 | 48,750 | ||
| 2022-01-31 | Wasman Jane Director | Grant or award | +1,900 | 1,900 | ||
| 2022-01-31 | Wasman Jane Director | Grant or award · Stock Option (Right to Buy) | +7,125 | 7,125 | ||
| 2022-01-31 | Varian John Director | Grant or award | +1,900 | 1,900 | ||
| 2022-01-31 | Varian John Director | Grant or award · Stock Option (Right to Buy) | +7,125 | 7,125 | ||
| 2022-01-31 | VAN NOSTRAND ROBERT L Director | Grant or award | +1,900 | 1,900 | ||
| 2022-01-31 | VAN NOSTRAND ROBERT L Director | Grant or award · Stock Option (Right to Buy) | +7,125 | 7,125 | ||
| 2022-01-31 | Stergiou Angelos M. President and CEO | Grant or award | +44,000 | 165,167 | ||
| 2022-01-31 | Stergiou Angelos M. President and CEO | Grant or award · Stock Option (Right to Buy) | +165,000 | 165,000 | ||
| 2022-01-31 | SCHEINBERG DAVID A Director | Grant or award | +1,900 | 2,082 | ||
| 2022-01-31 | SCHEINBERG DAVID A Director | Grant or award · Stock Option (Right to Buy) | +7,125 | 7,125 | ||
| 2022-01-31 | Burns John Thomas Senior VP, Finance & CAO | Grant or award | +9,600 | 27,244 | ||
| 2022-01-31 | Burns John Thomas Senior VP, Finance & CAO | Grant or award · Stock Option (Right to Buy) | +36,000 | 36,000 | ||
| 2021-12-02 | Stergiou Angelos M. President and CEO | Sale | −2,120 | $6.25 | $13K | 121,167 |
| 2021-12-02 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Sale | −847 | $6.25 | $5K | 42,028 |
| 2021-12-02 | Burns John Thomas VP, Finance & Corp Controller | Sale | −231 | $6.27 | $1K | 17,644 |
| 2021-03-04 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Grant or award | +7,875 | 32,875 |
Page 5 of 8 · 141 trades